Early Stage PD: It's Time to Know Your Options

This insert is designed to provide you with study-specific information about the TemPo-1 Study, including an overview of study participation, study drug dosing, and what you can expect as a study participant. If you have any questions after reviewing this insert, please speak with a member of the study team. They will be happy to answer your questions!

What is the TemPo-1 Study?

The TemPo-1 Study is a clinical research study focused on people with early stages of PD (diagnosed within the past three years) who are not currently taking levodopa or dopamine agonists to treat or manage symptoms.

This clinical research study is evaluating an investigational drug (tavapadon) to see if it may improve PD symptoms that impact your movement and daily activities.

You may be eligible to participate in TemPo-1 if you meet the following eligibility criteria:

40 to 80 years of age (inclusive)

Have been diagnosed with PD within the past three years

Are not *currently* taking levodopa and certain other PD medications

About the Study Drugs

Eligible study participants in the TemPo-1 Study will be randomly assigned (like flipping a coin) to receive one of the following study drugs:

A lower dose of the investigational drug

A higher dose of the investigational drug

Placebo

Study participants will have a 2-in-3 chance (67%) of receiving the investigational drug, and a 1-in-3 chance (33%) of receiving placebo.



Neither you nor the study doctor will know if you are receiving the investigational drug or placebo, or what dose of the investigational drug you may be receiving. However, the study doctor can find out this information if he or she feels it is necessary for your health.

As a study participant, you will take your assigned study drug every day for approximately 27 weeks and attend regularly scheduled study visits to monitor your health and the effects (if any) of your assigned study drug.

Open-label Extension (Optional)

Upon completing the Study Treatment Period, you may have the option to participate in an Open-label Extension study. During the extension, all study participants will receive the investigational drug for an additional 58 weeks and attend regularly scheduled study visits to monitor your health.

If you are interested, ask to speak to a study staff member to learn more about this opportunity.
